Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D Status, Inflammation and Cardiovascular Risk Markers: Study Summary

Previous related pageVitamin D Status, Inflammation and Cardiovascular Risk Markers: Full StudyNext related pageVitamin D Status, Inflammation and Cardiovascular Risk Markers: Full Study
Study at a glance

Do vitamin D supplements change blood signs of inflammation?

Researchers examined whether vitamin D supplements change selected blood signs of inflammation. The main analysis included 1,054 older adults in the VITAL trial, assigned vitamin D3 or placebo. Their average age was about 65, and only 17% started with vitamin D below 20 ng/mL. This was not a trial limited to people with very low vitamin D.

Which inflammation measurements changed with vitamin D3?

After two years, one inflammation-related marker, C-reactive protein measured with a high-sensitivity test, was lower with vitamin D3. The other three markers did not show significant effects. After four years, none showed a significant treatment effect. The precise size of the two-year change needs caution because two ways of expressing the published result give slightly different percentages. Neither percentage describes a reduction in heart attacks or strokes.

Why is the vitamin D and inflammation finding limited?

Fewer samples were available after four years, and many measurements of one marker could not be used. A separate analysis excluding some participants based on pill use did not meet the same statistical standard after allowing for multiple tests. The researchers did not establish that people with lower starting vitamin D benefited more. A separate one-year VITAL analysis found no reduction in its three markers, and one rose. That result alone does not show harm to health.

Do these results show lasting protection against heart attacks or strokes?

The studies used different selected groups and some different measurements. They do not show a simple sequence in which inflammation rises, falls and returns. Observational links between low vitamin D and later heart and circulation problems also do not prove that supplements will reduce those problems. The evidence supports a limited two-year blood-marker finding, not a broad, lasting reduction in inflammation or a dose or blood target for preventing heart attacks and strokes.

Read the full article below ↓

Low vitamin D status, inflammatory blood markers and cardiovascular events measure different things. The VITAL biomarker studies tested whether assigned supplements changed selected inflammatory markers. Their results differed across markers and follow-up times, and did not establish cardiovascular protection from a marker change. For the detailed methods and appraisal, read Vitamin D Status, Inflammation and Cardiovascular Risk Markers: Full Study.

Why low status does not prove a treatment benefit

In the Framingham Offspring cohort, Wang and colleagues followed 1,739 adults without prior cardiovascular disease. Low baseline vitamin D was associated with later cardiovascular events: below 15 ng/mL, the adjusted hazard ratio was 1.62, with a 95% confidence interval of 1.11-2.36, compared with higher concentrations.

That hazard ratio describes relative occurrence over follow-up. It is not the proportion of participants who had an event or a predicted percentage benefit from supplements.

This was an observational association, not a supplementation experiment. Participants with different vitamin D concentrations could differ in other ways affecting risk. The distinction between vitamin D status and vitamin D effect explains why raising a blood concentration cannot be assumed to reverse an observed risk association.

What the principal biomarker study tested

Dong and colleagues analysed 1,054 Boston-area participants in VITAL, a randomised, blinded trial. They compared daily vitamin D3 at 2,000 IU with placebo, within a design that also separately assigned marine omega-3 fatty acids. The average participant was about 65 years old. Only 17% had baseline vitamin D concentrations below 20 ng/mL.

The researchers measured high-sensitivity C-reactive protein, hs-CRP, and three cytokines: IL-6, IL-10 and TNF-α. Cytokines are signalling proteins. These selected blood markers do not represent every aspect of inflammatory signalling within tissues. Samples were assessed at baseline, two years and four years.

What changed, and what did not

Vitamin D3 was associated with a lower hs-CRP trajectory at two years. The nominal P value was 0.007, and the result remained significant after the study’s correction for testing four markers. The other three markers did not show significant vitamin D effects. At four years, none of the four markers showed a significant treatment effect.

The authors described the two-year hs-CRP result as a 19% reduction. Their rounded log-scale coefficient corresponds to about 16% under the usual conversion, so the precise percentage needs caution. Neither percentage is a measured reduction in heart attacks or strokes. The Full Study explains this reporting nuance and the distinction between a marker and a clinical outcome.

Why the qualifications matter

There were 977 samples at year two and 685 at year four, compared with 1,051 at baseline. In addition, 29% of IL-6 measurements fell outside the assay’s quantification limits and were excluded. These limitations affect how confidently the later and marker-specific findings can be interpreted.

An analysis excluding participants with low adherence or substantial outside supplementation retained the direction of the two-year hs-CRP finding, but did not remain significant after multiple-comparison correction. Exploratory subgroup analyses also did not establish a different treatment effect according to baseline vitamin D status or the other investigated characteristics.

How the earlier results compare

Costenbader and colleagues studied 1,561 VITAL participants with paired baseline and one-year samples. Vitamin D did not significantly lower hs-CRP, IL-6 or TNFR2, a receptor-related marker distinct from TNF-α. IL-6 instead showed a net relative increase of about 8.2%, with a 95% confidence interval of 1.5%-15.3%. This does not by itself demonstrate clinical harm.

The earlier and later analyses used different selected cohorts, sample handling and some different markers. Their findings cannot establish a simple sequence in which inflammation rises at one year, falls at two years and returns at four years.

What readers can conclude

The relevance to heart physiology is that inflammatory signals, vitamin D status and clinical events need separate evidence. The trials support a limited two-year hs-CRP finding, not a uniform anti-inflammatory effect or proven cardiovascular prevention. They do not define a supplement dose or blood target for preventing heart attacks and strokes.

Scientific sources

Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.

Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.

Related reading

Original sources

Source

Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial

Background: The VITAL study was a nationwide, randomized, double-blind, placebo-controlled, 2 × 2 factorial trial of vitamin D3 (2000 IU/day) and marine n-3 FAs (1 g/day) supplements.

Publication details

Dong Y, Zhu H, Chen L, Huang Y, Christen W, Cook NR, Copeland T, Mora S, Buring JE, Lee IM, Costenbader KH, Manson JE. Effects of Vitamin D3 and Marine Omega-3 Fatty Acids Supplementation on Biomarkers of Systemic Inflammation: 4-Year Findings from the VITAL Randomized Trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. Principal appraisal, including the supplementary subgroup figure.

Read more →
Source

Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults

Published in Clinical Chemistry (2019).

Publication details

Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, Kotler G, Camargo CA Jr, Manson JE, Cook NR. Effects of One Year of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic Inflammation in Older US Adults. Clinical Chemistry. 2019;65(12):1508-1521. DOI: 10.1373/clinchem.2019.306902. PMID: 31699704. Earlier VITAL biomarker comparison.

Read more →
Source

Vitamin D Deficiency and Risk of Cardiovascular Disease

Published in Circulation (2008).

Publication details

Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D’Agostino RB, Wolf M, Vasan RS. Vitamin D Deficiency and Risk of Cardiovascular Disease. Circulation. 2008;117(4):503-511. DOI: 10.1161/CIRCULATIONAHA.107.706127. PMID: 18180395. Observational background; the cohort finding is used to distinguish association from intervention evidence.

Read more →